Advertisement

Triple-Negative Breast Cancer: Clinical Features

  • Tira Tan
  • Rebecca Dent
Chapter

Abstract

Triple-negative breast cancers (TNBCs) lack expression of the three prognostic and predictive biomarkers routinely used in clinical management. It is a heterogeneous disease and clinically has aggressive tumor biology with the worst disease-specific outcomes as compared to other breast cancer subtypes. The clinical management of TNBC represents an important challenge, and limited treatment strategies are an unmet clinical need. These cancers do not respond to endocrine agents or targeted agents. Chemotherapy is the mainstay of treatment. This chapter describes the epidemiology, risk factors, clinical features, natural history, and prognosis of TNBC.

Keywords

Triple-negative breast cancer Epidemiology Natural history Triple-negative paradox 

References

  1. 1.
    Allred DC. Issues and updates: evaluating estrogen receptor-alpha, progesterone receptor, and HER2 in breast cancer. Mod Pathol. 2010;23(Suppl 2 (S2)):S52–9.CrossRefPubMedGoogle Scholar
  2. 2.
    Hammond MEH, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med. 2010;134(6):907–22.PubMedPubMedCentralGoogle Scholar
  3. 3.
    Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31 VN-r(31):3997–4013.CrossRefGoogle Scholar
  4. 4.
    Penault-Llorca F, Viale G. Pathological and molecular diagnosis of triple-negative breast cancer: a clinical perspective. Ann Oncol. 2012;23(Suppl. 6):vi19–22.PubMedGoogle Scholar
  5. 5.
    Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121(7):2750–67.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Lehmann BD, Jovanović B, Chen X, Estrada MV, Johnson KN, Shyr Y, et al. Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection. PLoS One. 2016;11(6):1–22.CrossRefGoogle Scholar
  7. 7.
    Burstein MD, Tsimelzon A, Poage GM, Covington KR, Contreras A, Fuqua S, et al. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin Cancer Res. 2014;21(i):1688–99.PubMedPubMedCentralGoogle Scholar
  8. 8.
    Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747–52.CrossRefPubMedGoogle Scholar
  9. 9.
    Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295(21):2492.CrossRefPubMedGoogle Scholar
  10. 10.
    Boyle P. Triple-negative breast cancer: epidemiological considerations and recommendations. Ann Oncol. 2012;23(Suppl. 6):8–13.Google Scholar
  11. 11.
    Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC CancerBase No. 11. International Agency for Research on Cancer: Lyon; 2013.Google Scholar
  12. 12.
    Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363:1938–48.CrossRefPubMedGoogle Scholar
  13. 13.
    Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13(15):4429–34.CrossRefPubMedGoogle Scholar
  14. 14.
    Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer. 2007;109(9):1721–8.CrossRefPubMedGoogle Scholar
  15. 15.
    Harris LN, Broadwater G, Lin NU, Miron A, Schnitt SJ, Cowan D, et al. Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342. Breast Cancer Res. 2006;8(6):R66.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Howlader N, Altekruse SF, Li CI, Chen VW, Clarke CA, Ries LAG, et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst. 2014;106(5). pii: dju055.Google Scholar
  17. 17.
    Villarreal-Garza C, Alvarez-Gómez RM, Pérez-Plasencia C, Herrera LA, Herzog J, Castillo D, et al. Significant clinical impact of recurrent BRCA1 and BRCA2 mutations in Mexico. Cancer. 2015;121(3):372–8.CrossRefPubMedGoogle Scholar
  18. 18.
    Lara-Medina F, Pérez-Sánchez V, Saavedra-Pérez D, Blake-Cerda M, Arce C, Motola-Kuba D, et al. Triple-negative breast cancer in Hispanic patients: high prevalence, poor prognosis, and association with menopausal status, body mass index, and parity. Cancer. 2011;117(16):3658–69.CrossRefPubMedGoogle Scholar
  19. 19.
    Brewster AM, Chavez-MacGregor M, Brown P. Epidemiology, biology, and treatment of triple-negative breast cancer in women of African ancestry. Lancet Oncol. 2014;15(13):e625–34.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Huo D, Ikpatt F, Khramtsov A, Dangou JM, Nanda R, Dignam J, et al. Population differences in breast cancer: survey in indigenous african women reveals over-representation of triple-negative breast cancer. J Clin Oncol. 2009;27(27):4515–21.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Sineshaw HM, Gaudet M, Ward EM, Flanders WD, Desantis C, Lin CC, et al. Association of race/ethnicity, socioeconomic status, and breast cancer subtypes in the National Cancer Data Base (2010-2011). Breast Cancer Res Treat. 2014;145(3):753–63.CrossRefPubMedGoogle Scholar
  22. 22.
    Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol. 2007;25(11):1329–33.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    KB K, JL H, DR B. al et. Risks of breast, ovarian, and contralateral breast cancer for brca1 and brca2 mutation carriers. JAMA. 2017;317(23):2402–16.CrossRefGoogle Scholar
  24. 24.
    Hall MJ, Reid JE, Burbidge LA, Pruss D, Deffenbaugh AM, Frye C, et al. BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer. Cancer. 2009;115(10):2222–33.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Comen E, Davids M, Kirchhoff T, Hudis C, Offit K, Robson M. Relative contributions of BRCA1 and BRCA2 mutations to “triple-negative” breast cancer in Ashkenazi Women. Breast Cancer Res Treat. 2011;129(1):185–90.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Warner E, Foulkes W, Goodwin P, Meschino W, Blondal J, Paterson C, et al. Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer. J Natl Cancer Inst. 1999;91(14):1241–7.CrossRefPubMedGoogle Scholar
  27. 27.
    Greenup R, Buchanan A, Lorizio W, Rhoads K, Chan S, Leedom T, et al. Prevalence of BRCA mutations among women with Triple-Negative Breast Cancer (TNBC) in a Genetic Counseling Cohort. Ann Surg Oncol. 2013;20(10):3254–8.CrossRefPubMedGoogle Scholar
  28. 28.
    Millikan RC, Newman B, Tse CK, Moorman PG, Conway K, Smith LV, et al. Epidemiology of basal-like breast cancer. Breast Cancer Res Treat. 2008;109(1):123–39.CrossRefPubMedGoogle Scholar
  29. 29.
    Shinde SS, Forman MR, Kuerer HM, Yan K, Peintinger F, Hunt KK, et al. Higher parity and shorter breastfeeding duration. Cancer. 2010;116(21):4933–43.CrossRefPubMedGoogle Scholar
  30. 30.
    Kwan ML, Kushi LH, Weltzien E, Maring B, Kutner SE, Fulton RS, et al. Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors. Breast Cancer Res. 2009;11(3):R31.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Reis-Filho JS, Tutt ANJ. Triple negative tumours: a critical review. Histopathology. 2008;52(1):108–18.CrossRefPubMedGoogle Scholar
  32. 32.
    Kassam F, Enright K, Dent R, Dranitsaris G, Myers J, Flynn C, et al. Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design. Clin Breast Cancer. 2009;9(1):29–33.CrossRefPubMedGoogle Scholar
  33. 33.
    Aapro M, Wildiers H. Triple-negative breast cancer in the older population. Ann Oncol. 2012;23(Suppl. 6):vi52–5.PubMedGoogle Scholar
  34. 34.
    Zhu W, Perez EA, Hong R, Li Q, Xu B. Age-related disparity in immediate prognosis of patients with triple-negative breast cancer: a population-based study from SEER cancer registries. PLoS One. 2015;10(5):1–15.Google Scholar
  35. 35.
    Syed BM, Green AR, Nolan CC, Morgan DAL, Ellis IO, Cheung KL. Biological characteristics and clinical outcome of triple negative primary breast cancer in older women – comparison with their younger counterparts. PLoS One. 2014;9(7):e100573.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Cameron D, Brown J, Dent R, Jackisch C, Mackey J, Pivot X, et al. Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. Lancet Oncol. 2013;14(10):933–42.CrossRefPubMedGoogle Scholar
  37. 37.
    Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007;13(8):2329–34.CrossRefPubMedGoogle Scholar
  38. 38.
    Masuda N, Lee S-J, Ohtani S, Im Y-H, Lee E-S, Yokota I, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 2017;376(22):2147–59.CrossRefPubMedGoogle Scholar
  39. 39.
    Adams S, Schmid P, Rugo HS, Winer EP, Loirat D, Awada A, et al. Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A. American Society of Clinical Oncology Annual Meeting; 2017.Google Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  1. 1.Division of Medical OncologyNational Cancer Centre SingaporeSingaporeSingapore

Personalised recommendations